These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31712212)

  • 1. Exebacase Demonstrates
    Watson A; Sauve K; Cassino C; Schuch R
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712212
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017.
    Traczewski M; Oh J; Cassino C; Schuch R
    Diagn Microbiol Infect Dis; 2019 Dec; 95(4):114879. PubMed ID: 31466875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in a Neutropenic Murine Thigh Infection Model.
    Asempa TE; Abdelraouf K; Carabeo T; Schuch R; Nicolau DP
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant
    Indiani C; Sauve K; Raz A; Abdelhady W; Xiong YQ; Cassino C; Bayer AS; Schuch R
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exebacase Is Active
    Swift SM; Sauve K; Cassino C; Schuch R
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0272320. PubMed ID: 34228536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).
    Fowler VG; Das AF; Lipka-Diamond J; Ambler JE; Schuch R; Pomerantz R; Cassino C; Jáuregui-Peredo L; Moran GJ; Rupp ME; Lachiewicz AM; Kuti JL; Wise RA; Kaye KS; Zervos MJ; Nichols WG
    Clin Infect Dis; 2024 Jun; 78(6):1473-1481. PubMed ID: 38297916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics.
    Oh J; Warner M; Ambler JE; Schuch R
    Microbiol Spectr; 2023 Mar; 11(2):e0526122. PubMed ID: 36862002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lytic activity of recombinant phage lysin LysKΔamidase against staphylococcal strains associated with bovine and human infections in the Jiangsu province of China.
    Zhou Y; Zhang H; Bao H; Wang X; Wang R
    Res Vet Sci; 2017 Apr; 111():113-119. PubMed ID: 28235706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections.
    McCarthy MW
    Drugs R D; 2022 Jun; 22(2):113-117. PubMed ID: 35175568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.
    Moorthy GS; Greenberg RG; Hornik CD; Cassino C; Ghahramani P; Kumar KR; Fowler VG; Cohen-Wolkowiez M
    Clin Infect Dis; 2022 Aug; 75(2):338-341. PubMed ID: 34894129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.
    Fowler VG; Das AF; Lipka-Diamond J; Schuch R; Pomerantz R; Jáuregui-Peredo L; Bressler A; Evans D; Moran GJ; Rupp ME; Wise R; Corey GR; Zervos M; Douglas PS; Cassino C
    J Clin Invest; 2020 Jul; 130(7):3750-3760. PubMed ID: 32271718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC; Foster-Frey J; Donovan DM
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnosic acid acts synergistically with gentamicin in killing methicillin-resistant Staphylococcus aureus clinical isolates.
    Vázquez NM; Fiorilli G; Cáceres Guido PA; Moreno S
    Phytomedicine; 2016 Nov; 23(12):1337-1343. PubMed ID: 27765353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exebacase in Addition to Daptomycin against MRSA.
    Kebriaei R; Stamper KC; Lev KL; Morrisette T; Abdul-Mutakabbir JC; Schuch R; Lehoux D; Rybak MJ
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0012821. PubMed ID: 34398668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography.
    Shah SU; Xiong YQ; Abdelhady W; Iwaz J; Pak Y; Schuch R; Cassino C; Lehoux D; Bayer AS
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis.
    Watson A; Oh JT; Sauve K; Bradford PA; Cassino C; Schuch R
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Yu XH; Song XJ; Cai Y; Liang BB; Lin DF; Wang R
    J Antibiot (Tokyo); 2010 Nov; 63(11):657-9. PubMed ID: 20877368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus.
    Xu-hong Y; Falagas ME; Dong W; Karageorgopoulos DE; De-feng L; Rui W
    J Antibiot (Tokyo); 2014 May; 67(5):369-71. PubMed ID: 24517925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents.
    López Díaz MC; Ríos E; Rodríguez-Avial I; Simaluiza RJ; Picazo JJ; Culebras E
    Int J Antimicrob Agents; 2017 Aug; 50(2):191-196. PubMed ID: 28577932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus.
    Daniel A; Euler C; Collin M; Chahales P; Gorelick KJ; Fischetti VA
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1603-12. PubMed ID: 20086153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.